These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27536319)

  • 41. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis.
    Romanovsky E; Kluck K; Ourailidis I; Menzel M; Beck S; Ball M; Kazdal D; Christopoulos P; Schirmacher P; Stiewe T; Stenzinger A; Budczies J
    Cell Death Discov; 2023 Apr; 9(1):126. PubMed ID: 37059713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
    Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
    Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
    Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA
    Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
    Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
    OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
    Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
    Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
    Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
    Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
    Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
    Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p53 Adenovirus as Gene Therapy for Ovarian Cancer.
    Carroll JL; Michael Mathis J; Bell MC; Santoso JT
    Methods Mol Med; 2001; 39():783-92. PubMed ID: 21340840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    Transl Oncol; 2018 Oct; 11(5):1171-1187. PubMed ID: 30059832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of Novel Somatic
    Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
    Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different mutation profiles associated to P53 accumulation in colorectal cancer.
    López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
    Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
    Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
    Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth.
    Haricharan S; Brown P
    Proc Natl Acad Sci U S A; 2015 Jun; 112(25):E3216-25. PubMed ID: 26063617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TP53 and mutations in human cancer.
    Szymańska K; Hainaut P
    Acta Biochim Pol; 2003; 50(1):231-8. PubMed ID: 12673364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer.
    Güran S; Pak I
    Cancer Genet Cytogenet; 1999 Mar; 109(2):108-13. PubMed ID: 10087941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.